Study: Roflumilast cream 0.05% is safe, effective in young children with eczema
Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...
Maintenance of low eczema activity seen after about 80 days off tapinarof
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
Healio7d
Adults, children maintain mild AD during treatment-free period follow Vtama cream 1%
Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...
The American Journal of Managed Care2d
Atopic Dermatitis Treatment Strategies Using Ruxolitinib, Considering Crucial Role of Skin Microbiome
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Nasdaq8d
Arcutis Biotherapeutics Presents Positive Data on ZORYVE® Cream and Foam for Atopic Dermatitis and Psoriasis at 2025 AAD Annual Meeting
Approximately 35 million individuals in the U.S. suffer from atopic dermatitis and psoriasis, highlighting a substantial market opportunity for ZORYVE products. Recognition of ZORYVE cream for ...
Managed Healthcare Executive7d
Drug Holidays Possible with Vtama in Atopic Dermatitis
A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...
HealthDay1d
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...